Immune and Fibrotic Systems

The term Immune and Fibrotic Systems refers to a broad therapeutic area and a complex network of biological processes rather than a single molecular target. This system is defined by the intricate crosstalk between immune cells, such as macrophages and T-lymphocytes, and the fibrotic response driven by fibroblasts and myofibroblasts (PMC7911435). In a healthy physiological state, these systems coordinate to manage tissue repair and wound healing; however, chronic dysregulation leads to the excessive deposition of extracellular matrix components, resulting in organ scarring and dysfunction. Pathological activation of this axis is a central driver in diseases such as idiopathic pulmonary fibrosis, nonalcoholic steatohepatitis (NASH), and systemic sclerosis (ResearchGate, 2026). While many pharmaceutical agents are developed to treat conditions within this category, they act on specific molecular targets like TGF-beta, various interleukins, or kinases rather than the system as a whole. Consequently, this entry is considered incorrect for a specific target profile as it lacks the molecular specificity required for drug-target interaction analysis.

Other names

Immune-fibrotic axisImmune-fibrotic crosstalkImmune-fibrotic network

Not applicable as this is a broad therapeutic area or physiological system rather than a specific molecular target.